AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

医学 恩扎鲁胺 前列腺癌 内科学 肿瘤科 危险系数 比例危险模型 循环肿瘤细胞 雄激素受体 前列腺特异性抗原 逻辑回归 置信区间 泌尿科 癌症 转移
作者
Anna Katharina Seitz,Silvia Thoene,Andreas Bietenbeck,Roman Nawroth,Robert Tauber,Mark Thalgott,Sebastian C. Schmid,Ramona Secci,Margitta Retz,Jürgen E. Gschwend,Jürgen Ruland,Christof Winter,Matthias Heck
出处
期刊:European Urology [Elsevier BV]
卷期号:72 (5): 828-834 被引量:92
标识
DOI:10.1016/j.eururo.2017.07.024
摘要

It has been demonstrated that androgen receptor splice variant 7 (AR-V7) expression in circulating tumor cells (CTCs) predicts poor treatment response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide. To develop a practical and robust liquid profiling approach for direct quantification of AR-V7 in peripheral whole blood without the need for CTC capture and to determine its potential for predicting treatment response in mCRPC patients. Whole blood samples from a prospective biorepository of 85 mCRPC patients before treatment initiation with abiraterone (n = 56) or enzalutamide (n = 29) were analyzed via droplet digital polymerase chain reaction. The association of AR-V7 status with prostate-specific antigen (PSA) response defined by PSA decline ≥50% and with PSA–progression-free survival (PSA-PFS), clinical PFS, and overall survival (OS) was assessed. High AR-V7 expression levels in whole blood were detectable in 18% (15/85) of patients. No patient with high AR-V7 expression achieved a PSA response, and AR-V7 status was an independent predictor of PSA response in multivariable logistic regression analysis (p = 0.03). High AR-V7 expression was associated with shorter PSA-PFS (median 2.4 vs 3.7 mo; p < 0.001), shorter clinical PFS (median 2.7 vs 5.5 mo; p < 0.001), and shorter OS (median 4.0 vs. 13.9 mo; p < 0.001). On multivariable Cox regression analysis, high AR-V7 expression remained an independent predictor of shorter PSA-PFS (hazard ratio [HR] 7.0, 95% confidence interval [CI] 2.3–20.7; p < 0.001), shorter clinical PFS (HR 2.3, 95% CI 1.1–4.9; p = 0.02), and shorter OS (HR 3.0, 95% CI 1.4–6.3; p = 0.005). Testing of AR-V7 mRNA levels in whole blood is a simple and promising approach to predict poor treatment outcome in mCRPC patients receiving abiraterone or enzalutamide. We established a method for determining AR-V7 status in whole blood. This test predicted treatment resistance in patients with metastatic castration-resistant prostate cancer undergoing treatment with abiraterone or enzalutamide. Prospective validation is needed before application to clinical practice.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
li完成签到,获得积分10
1秒前
1秒前
木子发布了新的文献求助10
2秒前
钟嘉霖完成签到,获得积分10
2秒前
小小发布了新的文献求助100
3秒前
Maestro_S的应助被Kenny采纳,获得10
3秒前
天际小山完成签到,获得积分10
5秒前
5秒前
xing发布了新的文献求助10
5秒前
6秒前
丁鹏笑完成签到 ,获得积分0
6秒前
孟昊如完成签到,获得积分10
6秒前
null的应助被aaa采纳,获得10
7秒前
8秒前
10秒前
英姑的应助被aoa采纳,获得10
11秒前
12秒前
12秒前
清汐完成签到 ,获得积分10
12秒前
那当然完成签到 ,获得积分10
13秒前
13秒前
苗浩阳完成签到,获得积分10
15秒前
Shirley发布了新的文献求助10
16秒前
ChaseY完成签到 ,获得积分10
17秒前
xing发布了新的文献求助10
17秒前
科目三的应助被sinmon采纳,获得10
18秒前
WK完成签到,获得积分10
18秒前
19秒前
执着的青烟完成签到,获得积分10
19秒前
19秒前
19秒前
ice完成签到 ,获得积分10
20秒前
舔舔给舔舔的求助进行了留言
20秒前
21秒前
21秒前
22秒前
22秒前
Owen的应助被aaa采纳,获得30
22秒前
casual完成签到,获得积分10
23秒前
树袋熊完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160961
求助须知:如何正确求助?哪些是违规求助? 9555819
关于积分的说明 21730291
捐赠科研通 7750940
什么是DOI,文献DOI怎么找? 3427477
关于科研通互助平台的介绍 2552515
邀请新用户注册赠送积分活动 2471912